Objectives: Abnormal calcium handling is a general feature of cardiac hypertrophy and alteration in the expression of SR proteins has been suggested to be involved in this alteration. To determine the expression of the cardiac ryanodine receptor (Ry2) gene during compensatory hypertrophy, we studied the mRNA and protein accumulation in left ventricles from rats with 30 to 100% hypertrophy. Methods: Cardiac hypertrophy was obtained after 1 month of aortic constriction. Ry2 mRNA was analyzed by RNase protection assay, Northern and slot blots, and Ry2 protein by high-affinity ['Hlryanodine binding and Western blot. Results: We demonstrate that: (1) the cardiac Ry2 mRNA concentration is decreased by 50% in severe hypertrophy; (2) both the density of the high-affinity sites and the Ry2 protein level are decreased by 25%; (3) the decrease in the mRNA and protein levels and the number of high-affinity sites are highly correlated to the severity of hypertrophy. Conclusion: Our results suggest that, as for SR Ca'+ -ATPase, there is either a downregulation or a lack of upregulation of the gene coding for the Ry2 in compensatory hypertrophy. The decreased density of Ry2 may alter SR Ca'+ transport and contribute to the impaired Ca2+ handling by slowing the Ca*+ movements.
Introduction
The Ca'+ pool of the sarcoplasmic reticulum (SR) is the major source of Ca2+ required for cardiac contraction. Ca2+ release from this pool is activated by Ca2+ influx through voltage-gated Ca*+ channels and mediated by a Ca*' channel called the 'ryanodine receptor' (Ry) [l-3] . Recent molecular cloning analysis has revealed that three distinct genes encode the Ry (Ryl, Ry2 and Ry3) [4-61 and that heart muscle mainly expresses the cardiac Ry2, whereas fast or slow twitch skeletal muscle do not [5, 6] .
Abnormal Ca2+ handling and prolongation of Ca2+ transient in hypertrophied and failing hearts [7, 8] suggest alterations in SR function and in the mRNA content of SR Ca*+ transport proteins [9, 10] . Several groups have already described a decrease in SR Ca*+ uptake in animal models of compensatory hypertrophy and in human failing heart which has been related to a reduced expression of SR Ca*+-ATPase mRNA, protein and activity [9-161, although contradictory results have been reported by Movsevian et al. [17] . Concerning Ry2 gene expression, most of the results are focused either on mRNA accumulation or on the number of high-affinity binding sites and therefore did not allow a consistent comparison. In experimental models of compensatory cardiac hypertrophy and heart failure, a decrease in the number of high-affinity ryanodine-binding sites was observed in the rat, the ferret and the guinea pig [l&19] and in canine heart failure [20, 21] . However, in a well-defined genetic model of cardiac failure (i.e., myopathic Syrian hamster), three groups reported a two-fold increase in the number of ryanodine binding sites in microsomal preparations [22- 241, but Lachnit et al. [24] suggest that this increase was most likely due to the membrane preparation. In human failing hearts, the Ry2 mRNA levels were found to be decreased in all types of cardiopathies [25] , decreased in ischemic cardiomyopathy and unchanged in dilated cardiomyopathy [26] , whereas an inverse relationship between Ry2 and ANF mRNA levels has been reported by Arai et al. [12] . By contrast, Meyer et al. [ll] and Nimer et al. [27] recently reported that the protein accumulation and number of high-affinity binding sites were similar in non-failing and failing human hearts. Therefore, it is still unclear whether expression of the Ry2 gene is regulated during cardiac hypertrophy and failure, whether this regulation is transcriptional and/or postranscriptional or whether the decrease in the number of high-affinity sites in experimental models of cardiac hypertrophy could be artefacts due to experimental conditions.
In the present study, we have characterized Ry2 gene expression in compensatory cardiac hypertrophy in rat by combining mRNA and protein analysis. This study was performed on the aortic stenosis model of cardiac hypertrophy which was previously used for the characterization of the high-affinity Ry2 (19) . We accurately measured in control and hypertrophied left ventricles: (1) the accumulation of Ry2 mRNA by RNase protection assay, Northern and slot blots; (2) the number of high-affinity ryanodinebinding sites by ligand-binding assay; and (3) the Ry2 protein level by Western blot analysis. We have found a significant decrease in mRNA and protein levels which is correlated with the severity of cardiac hypertrophy.
Methods

Induction of hypertrophy
Hypertrophy of the left ventricle was induced in adult male Wistar rats (180-220 g) from Iffa Credo (Lyon, France) by banding the abdominal descending aorta above the renal artery [ 18,191. Sham-operated animals underwent an identical procedure except that the hemoclip was not placed around the aorta; they were referred to as 'controls'. Hearts from operated animals were paired with hearts from control animals. The rats were anesthetized with i.p. sodium pentobarbital (50 mg/kg) and sacrificed 30-40 days after surgery. The magnitude of the hypertrophy was estimated by comparison of the left ventricular weight to body weight ratio (LVW/BW) of the operated animals with that of the sham-operated animals. Only rat hearts with a percentage of LV hypertrophy 2 30% were selected for use in this study.
The studies were in accordance with the requirements of the French Ministry of Agriculture (executive order No. 87-848, authorization 02362).
RNA extraction and probes
Total cellular RNA was extracted from the frozen left ventricular myocardium according to the Chirgwin procedure [28] . The quality of each RNA sample was assessed by the ethidium bromide staining of 28s and 18s rRNA species after electrophoretic separation. 
RNase protection assay
Antisense-labelled Ry2 and GAPDH riboprobes were purified on a 5% polyacrylamide/SM urea gel; 0.3 ng of the Ry2 probe with a specific radioactivity of 7 X lo4 cpm/ng and 0.6 ng of the GAPDH probe with a specific radioactivity of 7 X lo4 cpm/ng were hybridized simultaneously with 5 pg of total cardiac RNA. RPA was carried out as described (Ambion), using 0.2 unit of RNase A and 10 units of RNase Tl. The labelled probes that hybridized to complementary RNA were protected from RNase A/T1 digestion and were separated on a 5% acrylamide/gM urea gel. The gel was then dried and exposed on a storage Phosphor screen for quantification with a Fujix Bio-Imaging Analyser System (BAS 1000) and on X-ray films (Hyperfilm, Amersham) at -80°C for autoradiography.
Northern and slot blots
Total cellular RNA (10 kg) from individual LV were size-fractionated by electrophoresis on a 1% agarose/formaldehyde gel, transferred to a Nylon Hybond-N mem-brane (Amersham), and cross-linked by ultraviolet irradiation (0.65).
Formaldehyde-denatured RNA from different tissues and known amounts of sense RNA probe transcribed in vitro from the Ry2 plasmid using the T3 RNA polymerase were directly spotted onto nylon filters (Hybond-N, Amersham, France) for slot blot analysis. Four concentrations of each RNA (3 to 20 pg) and 7 concentrations of synthetic Ry2 sense RNA (5 to 60 pg) were applied.
Northern and slot blots were sequentially hybridized to radiolabelled probes specific for Ry2, GAPDH, and 18s rRNA. Blots hybridized to the Ry2 and GAPDH probes were washed in 0.25XSSC-0.1% SDS at 50°C. Hybridization of the 18s probe was performed as previously described [lo] . Slot blots and Northern blots were exposed to a Phosphor screen with a Fujix Bio-Imaging Analyser System (BAS 1000).
Crude microsomal preparation
Each sample of myocardium was broken into small pieces in liquid nitrogen and the crude membrane preparations were then prepared according to Rannou et al. [19] . All fractionation procedures were performed at 4°C and in the presence of proteolytic enzyme inhibitors (0.7 p,M aprotinin, 0.7 p,M pepstatin, 1.1 pM leupeptin, 230 pM phenylmethane-sulfonyl fluoride, 1 mM iodoacetamide and 1 mM diisopropylfluorophosphate). Briefly, 0.3-0.5 g of myocardium were homogenized at 4°C using a Polytron PT 20, in 10 volumes of buffer containing 200 mM sucrose, 20 mM HEPES, 0.4 mM CaCl,, at pH 7.4. The homogenate was filtered through cheese cloth, diluted to 30 ml, and centrifuged at 41000 X g for 50 min in a Sorvall SS34 rotor. The pellet was resuspended at a protein concentration of 6-8 mg/ml in ice-cold buffer containing 0.1 M NaCl, 30 mM Imidazole, 8% sucrose, pH 6.8, and in presence of proteolytic enzyme inhibitors. Aliquots of the crude particulate preparations were stored in liquid nitrogen until use.
Measurement of 13Hlryanodine binding
The number of high-affinity binding sites was assessed, under conditions optimum for the heart as described by Briefly, crude particulate preparations (150 kg) were incubated at 37°C in 1 ml medium containing 1 M KCl, 10 p,M free calcium, 50 mM HEPES, 2 mM dithiothreitol and proteolytic enzyme inhibitors, pH 7.4. The free calcium concentration of the incubation medium was calculated by computer analysis. After 120 min incubation, solutions were filtered through a Whatman GF-B glass fiber filter in a Skatron apparatus, and the filter was rinsed with 3 X 5 ml of cold water. Total radioactivity and radioactivity remaining on the filter were counted after addition of 5 ml of scintillation fluid (Hionic fluor, Packard) in a LKB scintillation counter. Specific binding was obtained by subtracting the non-specific binding determined in the presence of 10 p,M cold ryanodine (Calbiochem) from total binding. Three binding experiments were performed in duplicate for each myocardial sample.
Western blot analysis
Quantification of the Ry2 present in crude particulate heart preparations was assessed using the Western Blot technique [29] . Anti-Ry antibodies were obtained by immunisation of a rabbit with Ry purified from pig skeletal muscle [30] . The polyclonal antiserum was specific for Ry from the heavy SR fraction, and reacts against homogenates from rat (Fig. 3) , pig and human hearts (data not shown). Thirty micrograms of heart proteins were loaded on a 5-15% polyacrylamide SDS gel. After electrophoretic separation, the proteins were transferred to Immobilon-P (Millipore) during 4 h at 1.1 A. The Immobilon sheets were incubated overnight at 4°C with the antibodies (dilution l/5000), then for 2 h at room temperature with horseradish peroxidase-conjugated anti-rabbit IgG (BioSource Int., CA, USA) and the reactive proteins were detected by a chemiluminescent reaction (Specichrom kit, SPECI S.A., France). After the immunogenic reaction, the Immobilon sheets were washed 5 X 5 min with a medium composed of 0.1 M sodium acetate (pH 4) and 0.5 M sodium chloride to eliminate the antibodies. The proteins transferred to Immobilon were then stained with Coomassie blue R250 (0.1% in 1% CH,COOH, 40% methanol) for 5 min. Non-specific staining was then suppressed by a 5-min wash in 10% CH,COOH, 50% methanol. Quantitation of the Ry specific band on autoradiography and bands of both proteins and myosin heavy chain (MyHC) stained with Coomassie blue were performed by densitometric analysis after scanning. Each individual value represents the mean of three independent determinations.
Statistical analysis
The values were expressed as mean + s.d. The various groups were compared by one-way analysis of variance (ANOVA analyses) and by unpaired Student's t-test. P < 0.05 was considered statistically significant. Table 1 shows the anatomical data of the sham-operated (control animals) and operated animals after 30-40 days of abdominal aortic constriction. Varying degrees of increase in cardiac mass can be demonstrated in operated animals. Therefore, they have been pooled in two groups: the first one exhibited moderate hypertrophy and consisted of animals in which the LVW/BW was between 2.29 and 2.64, and the second one exhibited severe hypertrophy and consisted of animals in which the LVW/BW was between 2.64 and 3.52. In this model, LV hypertrophy can be assumed to be a compensatory hypertrophy since the operated animals did not present any sign of heart failure, as determined by the absence of dyspnea, pulmonary edema or ascitis and the unchanged weight of the right ventricle.
Results
I. Cardiac hypertrophy
A B 1 2 3 18St 3.2. mRNA analyses Northern blots were hybridized with the cardiac Ry2 cDNA probe (Fig. 1A) . Total RNA isolated from hypertrophied and control LV (lanes 1 and 2, respectively) contained a unique transcript of approx. 16 kb, demonstrating the specificity of the probe. No signal could be detected in skeletal muscle RNA (lane 3). However, quantification of the mRNA level was not performed on Northern blots because transfer efficiency might be hazardous due to the high length of the transcript. Fig. IB shows a typical ribonuclease protection assay which is a highly sensitive and discriminative procedure to detect mRNA. Simultaneous detection of Ry2 and GAPDH mRNAs was performed in order to normalize the expression of Ry2 mRNA. As expected, the length of the undigested Ry2 and GAPDH RNA probes (lane 9, 591 bp and 185 bp, respectively) was longer than that of the protected fragment. After 30 min of exposure on a Phosphor screen, a protected fragment of GAPDH mRNA of 164 bp was detected in both control and hypertrophied rat hearts, as well as in skeletal muscle (lanes 1 to 7). After 2 h of exposure, a protected fragment of Ry2 mRNA of 541 bp was detected in RNA from both control and hypertrophied hearts from rat (lanes 1 to 6); no signal was detected in RNA from rat skeletal muscle (lane 7). When normalized by GAPDH mRNA, the level of Ry2 mRNA accumulation was decreased in four representative hypertrophied LV ( -35%, -25%, -37% and -20% in lanes 2, 3, 5 and 6, respectively) compared with two control LV from rat (lanes 1 and 4). Similar results have been obtained in four experiments and show a 20 f 12 and 50 + 9% decrease in moderate and severe hypertrophy, respectively. Of note, the difference was only significant in severe hypertrophy (P < 0.05).
Absolute quantification of Ry2 mRNA has been further 12 345678910 performed by slot blot analysis on total RNAs from 19 control, and 23 hypertrophied LV. Titration curves were obtained by plotting the absorbance values against the concentrations of in vitro synthesized Ry2 sense RNA probe (r = 0.9 1; P < 0.001). Densitometric scores of cardiac Ry2 mRNA were normalized to that of GAPDH mRNA or 18s rRNA. The amount of Ry2 mRNA in each sample was calculated from the standard curve and corrected for the length of the probe (1 pg of the 541-bp probe corresponds to 29.6 pg of the 16-kb Ry2 mRNA). The mean quantity of Ry2 mRNA in control LV, moderate and severe hypertrophy was 59.97 f 15.3, 46.46 f 16.4, and 29.77 + 3.21 pg per pg of total RNA, respectively (P < 0.01 in severe hypertrophy vs. control). In moderate hypertrophy, there is a non-significant trend towards a decrease in the Ry2 mRNA level (22 ) 16%) whereas in severe hypertrophy the Ry2 mRNA level is significantly decreased by 50 + 5%. Moreover, as shown in Fig. 2A , there is a significant correlation between Ry2 mRNA content and the LVW/BW ratio. The results were similar whether GAPDH or 18s rRNA probes were used to normalize the amount of total RNA applied in each well.
Protein analyses
The SR Ca" release channel has been shown to be a homotetramer and high-affinity ryanodine-binding sites are considered representative of one of these subunits. Nevertheless, it has been recently reported that binding might also depend on the purification procedure and on the presence of regulatory factors [24,3 1,321. To determine if there was a relationship between the number of high-affinity ryanodine-binding sites and the protein content, we therefore performed [ 3H]ryanodine binding experiments to measure the number of high-affinity sites and quantitative Western blot analysis to detect the four subunits of the Ca" release channel. The two sets of experiments were performed on the same crude microsomal preparations from control or hypertrophied hearts with severe hypertrophy (n = 6 in each group). The total protein yield of the preparation was similar in control and hypertrophied hearts (Table 2) . Moreover, we have previously shown that recovery of the Ry2 binding sites was complete in this crude microsomal preparation [ 191. According to the non-significant difference in Ry2 mRNA accumulation shown in this study, and to the non-significant decrease in high-affinity ryanodine-binding sites previously observed in moderate hypertrophy [19] , the analysis has been restricted to severe hypertrophy.
The number of high-affinity Ry2 is shown in Table 2 . It is expressed per mg protein of the preparation and calculated per gram LV according to the protein yield. The number of high-affinity sites per mg protein or per gram LV was significantly decreased by 23% in severe hypertrophy. The total number of sites per hypertrophied LV was not significantly different from control, although there was a trend towards an increase. Moreover, as shown in 2B, there was a significant correlation between the number of high-affinity Ry2 and the LVW/BW ratio. These results were consistent with our previous findings [19] . Fig. 3 shows representative results of Western blot analysis of Ry2 from control and hypertrophied hearts. Immunochemical detection of Ry2 revealed a single band at the expected position of 400 kDa, whereas that of Ry 1 from heavy SR of rabbit skeletal muscle was seen at 440 kDa as reported by Imagawa [l] . The data received from densitometric analysis were related to MyHC values from Coomassie blue staining of the blot. We found that Ry2 protein level was significantly reduced by 28% in severe hypertrophy. Similar results have been obtained after normalization with Coomassie blue staining of total protein extracts (data not shown). Moreover, the number of highaffinity Ry2 was significantly correlated to the level of Ry2 mRNA (Fig. 4A ) and of Ry2 protein (Fig. 4B) . 
Discussion
The major findings of this study on compensatory hypertrophy of the rat heart are: ( 1) the coordinated decrease in the mRNA, high-affinity binding sites, and protein levels of Ry2; (2) the correlation between these decreases and the degree of hypertrophy. Of note, the decrease in mRNA level is higher than that of high-affinity sites or protein level. The present data suggest either a downregulation or a lack of upregulation of the gene encoding the Ry2 isoform in the hypertrophied heart. Futhermore, on the same model of cardiac hypertrophy, similar findings have been reported for SR Ca*+-ATPase [ 14,161 which pumps back into SR the calcium which has been released by the SR Ca'+ release channel. Taken together, a coordinated regulation of these two genes might occur and might be an important feature in maintaining calcium homeostasis in the hypertrophied heart despite the resultant slowing of Ca2+ movements.
The present study complements our previous results on high-affinity Ry2 in compensated hypertrophy from rat, guinea pig and ferret heart [ 191. As shown by RNase protection assay, Northern and slot blots, severe hypertrophy induces a significant decrease in Ry2 mRNA, whereas a non-significant trend towards a decrease is observed in moderate hypertrophy. The decrease is independent of the normalization procedure and it is significantly correlated to the degree of hypertrophy ( Fig. 2A) . In moderate hypertrophy, the non-significant decrease in the relative level of accumulation of Ry2 mRNA might be due to the sensitivity limits of the techniques used. Due to the unchanged concentration of total mRNAs in hypertrophied hearts [33] , and to a similar yield of total RNA in control and hypertrophied LV, we can assume that the total amount of Ry2 mRNA per total LV is unchanged. Therefore, we suggest that the Ry2 gene expression is not stimulated by hemodynamic overload.
In the present study, we further demonstrate a coordinated decrease in the number of high-affinity sites and in the protein content of Ry2 in severe hypertrophy in the rat heart. Thus, even though the presence and the role of modulatory factors in the hypertrophied heart cannot be excluded [3 1,321, our results demonstrate that the number of high-affinity Ry2 is representative of the protein content. Furthermore, the higher decrease in mRNA than in protein content (50 and 25%, respectively) might suggest that regulation of the expression of the Ry2 gene during compensatory cardiac hypertrophy involves two steps: the first could be either the non-activation of the gene coding for Ry2 in opposition to the overall activation of the genes leading to cardiac hypertrophy [33] or an increase in mRNA degradation rates. The second step could reflect an increased rate of protein synthesis or, more likely, a decreased rate of degradation as already reported by Magid et al. [34] for myocardial protein synthesis. This coordinated regulation of the amounts of mRNA and protein might reflect compensatory responses by cardiac myocytes in order to maintain adaptation of the heart to hemodynamic overload. Our results are in good agreement with the decrease in Ry2 observed by Cory et al. [20] and Vatner et al. [21] in two models of canine heart failure due to rapid ventricular pacing. However, cardiac hypertrophy was not observed in these models and a downregulation of Ry2 might therefore be suspected. In failing human hearts, downregulation of Ry2 has not been clearly evidenced.
There is a trend towards a decrease in mRNA content [12, 25, 26] , although Brillantes et al. [26] reported an unchanged accumulation in dilated cardiomyopathy. Surprisingly. no significant differences in protein content were observed [ 1 1,271. The reason for the discrepancy in these observations is still unknown. At present, we cannot exclude the possibility that discrepancies might depend on the cause of heart failure or on the species or represent artefacts of tissue fractionation as reported by Lachnit et al. [24] in the cardiomyopathic Syrian hamster. In compensatory hypertrophy, parallel reductions in mRNA and protein levels of SR Ca*+-ATPase have been demonstrated [ 14,151. These reductions are only significant in severe (50%) compensatory hypertrophy, and suggest also that there is at least a lack of activation of Ca'+-ATPase gene expression. Interestingly, the present findings support the concept that altered calcium handling is observed in compensatory hypertrophy, and that it reflects a defect in both SR calcium accumulation and release. Reduced content of Ry2 and SR Ca2+-ATPase in hypertrophied myocytes is consistent with functional alterations observed in the hypertrophied heart: (1) prolongation of the calcium transient and the decrease in its peak value which have been described in myocytes isolated from hypertrophied and failing ventricular myocardium [7, 8, 35] ; (2) prolongation of the time to peak shortening and relaxation [lo] . This concerted decrease in the Ca'+ cycling proteins of the SR might represent an adaptive mechanism of the heart to mechanical overload by a parallel regulation of Ca'+ release and Ca'+ uptake. If the activity of the Ca'+ release channel is reduced as the content of Ry2, it might slow the rate of development of the Ca'+ transient as observed in cardiac hypertrophy and heart failure and therefore the time to reach peak tension. In the same way, a decreased Ca" uptake might slow the rate of decrease of the Ca*+ transient and the relaxation rate [lo] . Moreover, it has been suggested by Cory et al. [36] in dog heart failure that decreased Ca'+ release might improve calcium sequestration in the SR, even in the presence of a decrease in Ca2+ pump content, and therefore reduce the energy consumption. However, such an adaptation might become detrimental as soon as stress or working conditions require higher rates of Ca*+ cycling. In fact, we believe that the decrease in Ca'+ -ATPase and Ry2 levels which occur in compensatory hypertrophy might be the first step of the transition from compensatory hypertrophy to heart failure. These results are in agreement with the hypothesis previously proposed by Feldman et al. [37] and Kiss et al. [16] that the decrease in Ca'+-ATPase mRNA levels may be a marker of the transition from compensatory hypertrophy to failure.
Finally, the decrease in the mRNA and protein content of the severely hypertrophied LV in the rat strongly suggests that Ca'+ release might be altered and participate in the slowly developing increases in the magnitude of the Ca'+ transient and contraction.
